Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain.
Opioids and cannabinoids are among the most widely consumed drugs of abuse in humans and the phenomena of cross-tolerance or mutual potentiation have been demonstrated between the two drugs. Several authors have suggested that both drugs share common links in their molecular mechanisms of action, although this has been a matter of controversy. Furthermore, no data exist on the possible adaptive changes in the contents of arachidonoylethanolamide (anandamide, AEA) and 2-arachidonoylglycerol (2-AG), the two major endogenous ligands for cannabinoid receptors, in morphine-tolerant rats. In the present work, we investigated the alterations in cannabinoid receptor functionality and endocannabinoid levels in rats chronically treated with morphine (5 mg/kg, s.c., twice a day for 5 days). Autoradiographic-binding studies using [(3)H]CP-55 940 revealed a slight but significant reduction in cannabinoid receptor level in the cerebellum and hippocampus of morphine-tolerant rats, while CP-55 940-stimulated [(35)S]GTPgammaS binding showed a strong decrease (40%) in receptor/G protein coupling in the limbic area of these animals. Moreover, in the same brain regions we measured, by isotope-dilution gas chromatography/mass spectrometry, the contents of AEA and 2-AG. Chronic morphine exposure produced a strong reduction in 2-AG contents without changes in AEA levels in several brain regions (ie striatum, cortex, hippocampus, limbic area, and hypothalamus). These findings clearly demonstrate that prolonged activation of opioid receptors could alter the cannabinoid system, in terms of both receptor functionality and endocannabinoid levels, and suggest the involvement of this system, alone or in combination with other mediators, in the phenomenon of morphine tolerance.
Viganò
Daniela
D
DBSF, Pharmacology Unit, University of Insubria, Busto Arsizio (VA), Italy. daniela.parolaro@uninsubria.it
Grazia Cascio
Maria
M
Rubino
Tiziana
T
Fezza
Filomena
F
Vaccani
Angelo
A
Di Marzo
Vincenzo
V
Parolaro
Daniela
D
D000818:Animals; D001095:Arachidonic Acids; D001921:Brain / Q000187:drug effects* / Q000378:metabolism*; D063385:Cannabinoid Receptor Modulators; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D063388:Endocannabinoids; D005231:Fatty Acids, Unsaturated / Q000378:metabolism*; D005989:Glycerides / Q000378:metabolism*; D007279:Injections, Subcutaneous; D008297:Male; D009020:Morphine / Q000008:administration & dosage*; D018377:Neurotransmitter Agents / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley
D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D005231:Fatty Acids, Unsaturated; D005989:Glycerides; D018377:Neurotransmitter Agents; D009020:Morphine; C094503:glyceryl 2-arachidonate